Brii Biosciences Limited (2137.HK)
HKD 0.85
(0.0%)
HKD 0.85
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -594.01 Million | -496.27 Million | -879.45 Million | -403.71 Million | -67.27 Million |
| Net Income | -184.37 Million | -489.78 Million | -4.19 Billion | -1.28 Billion | -521.02 Million |
| Depreciation & Amortization | 15.67 Million | 17.03 Million | 17.26 Million | 14.2 Million | 7.49 Million |
| Deferred income taxes | - | - | -44.79 Million | 15.01 Million | -5.29 Million |
| Stock-based compensation | 64.22 Million | 77.92 Million | 79.37 Million | 29.48 Million | 23.38 Million |
| Change in working capital | -120.73 Million | -76.99 Million | -333.74 Million | 471.45 Million | 25.63 Million |
| Other non-cash items | -107.52 Million | -24.46 Million | 3.59 Billion | 349.63 Million | 402.54 Million |
| Investing Cash Flow | -104.35 Million | -1.43 Billion | -475.75 Million | -43.65 Million | -92.78 Million |
| Investments in PPE | -49.6 Million | -139.29 Million | -1.02 Million | - | -24.14 Million |
| Acquisitions | 56.02 Million | - | 1.62 Million | - | 143 Thousand |
| Investment purchases | -3.48 Billion | -2.1 Billion | -499.64 Million | -196.22 Million | -71.55 Million |
| Sales/Maturities of investments | 3.26 Billion | 774.81 Million | 20.1 Million | 153.69 Million | 5.09 Million |
| Other Investing Activities | 1.14 Million | 33.21 Million | 3.19 Million | -1.12 Million | -2.31 Million |
| Financing Cash Flow | -10.97 Million | -3.04 Million | 3.23 Billion | 657 Million | 518.34 Million |
| Debt repayment | -9.5 Million | -8.96 Million | -9.74 Million | -6.78 Million | -200 Thousand |
| Dividends payments | - | - | - | - | - |
| Common Stock Repurchased | -1.16 Million | -678 Thousand | - | - | - |
| Common Stock Issuance | 179 Thousand | 7.44 Million | 2.32 Billion | 144 Thousand | - |
| Other Financing Activities | -315 Thousand | 8.1 Million | 914.65 Million | 663.64 Million | 518.54 Million |
| Accounts receivables | - | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other working capital | -33.14 Million | -76.99 Million | -333.74 Million | 471.45 Million | 25.63 Million |
| Cash at beginning of period | 1.19 Billion | 2.85 Billion | 1.03 Billion | 880.35 Million | 521.11 Million |
| Cash at end of period | 489.65 Million | 1.19 Billion | 2.85 Billion | 1.03 Billion | 880.35 Million |
| Capital Expenditure | -49.6 Million | -139.29 Million | -1.02 Million | - | -24.14 Million |
| Effect of forex changes on cash | 8.41 Million | 267.96 Million | -54.79 Million | -55.02 Million | 950 Thousand |
| Net cash flow / Change in cash | -700.92 Million | -1.66 Billion | 1.82 Billion | 154.6 Million | 359.24 Million |
| Free Cash Flow | -643.62 Million | -635.57 Million | -880.48 Million | -403.71 Million | -91.42 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -140.26 Million | -140.26 Million | -184.37 Million | 7.54 Million | 7.54 Million | -94.95 Million |
| Depreciation & Amortization | 3.02 Million | 3.02 Million | 15.67 Million | 3.57 Million | 3.57 Million | 4.25 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | 1.56 Million | 1.56 Million | 64.22 Million | 15.69 Million | 15.69 Million | 17.84 Million |
| Change in working capital | - | - | -120.73 Million | -16.57 Million | -16.57 Million | - |
| Other non-cash items | 22.78 Million | 22.78 Million | -107.52 Million | -130.36 Million | -130.36 Million | -104.01 Million |
| Investing Cash Flow | 196.95 Million | 196.95 Million | -104.35 Million | 124.52 Million | 124.52 Million | -176.7 Million |
| Investments in PPE | -382.5 Thousand | -382.5 Thousand | -49.6 Million | - | - | - |
| Acquisitions | - | - | 56.02 Million | - | - | - |
| Investment purchases | - | - | -3.48 Billion | - | - | -1.43 Billion |
| Sales/Maturities of investments | - | - | 3.26 Billion | - | - | 1 Billion |
| Other Investing Activities | 197.33 Million | 197.33 Million | 1.14 Million | 124.52 Million | 124.52 Million | -176.7 Million |
| Financing Cash Flow | -2.21 Million | -2.21 Million | -10.97 Million | -3.09 Million | -3.09 Million | -2.39 Million |
| Debt repayment | - | - | -9.5 Million | - | - | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -1.16 Million | -581 Thousand | -581 Thousand | - |
| Common Stock Issuance | - | - | 179 Thousand | - | - | 147.02 Thousand |
| Other Financing Activities | -2.21 Million | -2.21 Million | -315 Thousand | -2.51 Million | -2.51 Million | -2.39 Million |
| Accounts receivables | - | - | - | - | - | - |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Other working capital | - | - | -33.14 Million | -16.57 Million | -16.57 Million | - |
| Cash at beginning of period | - | - | 1.19 Billion | - | - | 1.01 Billion |
| Cash at end of period | 83.3 Million | 83.3 Million | 489.65 Million | 1.07 Million | 1.07 Million | 528.01 Million |
| Capital Expenditure | -382.5 Thousand | -382.5 Thousand | -49.6 Million | - | - | - |
| Effect of forex changes on cash | 1.45 Million | 1.45 Million | 8.41 Million | -227.5 Thousand | -227.5 Thousand | 4.43 Million |
| Net cash flow / Change in cash | 83.3 Million | 83.3 Million | -700.92 Million | 1.07 Million | 1.07 Million | -487.86 Million |
| Free Cash Flow | -113.27 Million | -113.27 Million | -643.62 Million | -120.12 Million | -120.12 Million | -176.88 Million |
1504
NIRO
HLMS
PRMG
STS
0010